
68. A compound of Formula I,



(I)

or a pharmaceutically acceptable salt thereof ~~to a patient in need of such treatment~~,

wherein R_1, R_2, R_3, R_4 and R_5 are each independently

a) hydrogen;

b) halogen, -CN, $-CF_3$, or $-NO_2$;

c) C_1-C_8 alkyl or C_1-C_8 haloalkyl;

d) C_2-C_8 alkenyl or C_2-C_8 haloalkenyl;

e) C_2-C_8 alkynyl or C_2-C_8 haloalkynyl;

f) optionally substituted aryl or optionally substituted heteroaryl;

g) $-C(O)R_6$;

h) $-C(O)OR_6$, or $-CO_2R_6$;

i) $-OR_6$, $-O-L-OC(O)R_6$, or $-O-L-OC(O)OR_6$;

j) $-OC(O)R_6$, or $-OC(O)-L-OC(O)R_6$;

k) $-OC(O)OR_6$, $-OC(O)O-L-C(O)R_7$, $-OC(O)O-L-C(O)OR_7$, or $-L-OC(O)R_6$;

l) $-C(O)NR_6R_7$, or $-CNR_6R_7$;

m) $-OC(O)NR_6R_7$, $-OC(O)N(R_6)-L-OC(O)R_7$, $-OC(O)O-L-(R_6)-L-C(O)R_7$, $-OC(O)-C(R_6)(R_7)-L-OC(O)R_8$, $-OC(O)N(-L-OC(O)R_7)(-L-OC(O)R_8)$;

n) $-SR_6$, or $-NR_6R_7$;

o) $-NR_6C(O)R_7$;

p) $-NR_6C(O)OR_7$;





q) $-NR_6C(O)NR_7$;

r) $-OSO_2R_6$;


s) $-SO_2OR_6$;

t) $-SO_2R_6$;

u) $-NR_6SO_2R_7$;







,

,

, or

.

79. A compound of Formula II,


(II)

or a pharmaceutically acceptable salt thereof ~~to a patient in need of such treatment~~,

wherein A is $-OR_6$, $-CO_2R_6$, -L-OC(O)R_6, -O-L-OC(O)R_6, -O-L-OC(O)OR_6, -OC(O)R_6, -OC(O)-L-OC(O)R_6, -OC(O)OR_6, -OC(O)O-L-C(O)R_7, -OC(O)O-L-C(O)OR_7, -C(O)NR_6R_7, $-CNR_6R_7$, -OC(O)NR_6R_7, -OC(O)N(R_6)-L-OC(O)R_7, -OC(O)N(-L-OC(O)R_7)(-L-OC(O)R_8),


,

,

,

, or



; and

B and C are each independently hydrogen, halogen, $-CF_3$, -CN, C_1-C_8 alkyl, phenyl, $-OR_6$, or $-C(O)OR_6$, or B and C when taken together form an optionally substituted 4- to 8-membered carbocyclic or heterocyclic ring, wherein the ring is saturated, unsaturated or aromatic;

wherein m and n are each independently an integer from 0 to 2;

Y is $-CH_2-$, -O-, $-NR_7-$, or -S-;

p is an integer from 1 to 3;

Z is  or ;

each R_6 is independently hydrogen, C_1-C_8 alkyl, C_1-C_8 haloalkyl, C_2-C_8 alkenyl, C_2-C_8 haloalkenyl, C_2-C_8 alkynyl, C_2-C_8 haloalkynyl, an optionally substituted 4-8 membered saturated carbocyclic or heterocyclic ring, optionally substituted aryl, optionally substituted heteroaryl, -L-optionally substituted aryl or -L-optionally substituted heteroaryl;

L is C_1-C_8 alkyl;


R_{14} is hydrogen, halogen, C_1-C_8 alkyl, or C_1-C_8 alkoxyl;

R_7 and R_8 are each independently hydrogen or C_1-C_8 alkyl; or

R_6 and R_7 taken together form an optionally substituted 4- to 8-membered carbocyclic or heterocyclic ring, wherein the ring is saturated, unsaturated or aromatic,

for use in the treatment of osteoporosis, rheumatoid arthritis, osteoarthritis, Paget's disease, or alveolar bone loss.

80. A compound of Formula IV,




(IV)


or a pharmaceutically acceptable salt thereof ~~to a patient in need of such treatment~~,


wherein A is $-OR_6$, $-CO_2R_6$, -L-OC(O)R_6, -O-L-OC(O)R_6, -O-L-OC(O)OR_6, $-OC(O)R_6$, -OC(O)-L-OC(O)R_6, $-OC(O)OR_6$, -OC(O)O-L-C(O)R_7, -OC(O)O-L-C(O)OR_7, $-C(O)NR_6R_7$, $-CNR_6R_7$, $-OC(O)NR_6R_7$, -OC(O)N(R_6)-L-OC(O)R_7, -OC(O)N(-L-OC(O)R_7)(-L-OC(O)R_8),


for use in the treatment of osteoporosis, rheumatoid arthritis, osteoarthritis, Paget's disease, or alveolar bone loss.


81. The compound of claim 80, wherein the compound is a compound or a pharmaceutically acceptable salt or hydrate of a compound of Formula IVa, IVb, IVc, IVd, or IVe:


(IVa)



(IVb)


(IVc)



(IVd)


(IVe).


82. The ~~method~~ compound of claim 81, wherein the compound or a pharmaceutically acceptable salt or hydrate of a compound of Fomula IVa is a compound or a pharmaceutically acceptable salt or hydrate of a compound of Fomula IVf,


(IVf),

wherein R_9 is H, OH, or F; R_{10} is



or ;

and R_x is C_1-C_8 alkyl, C_1-C_8 alkoxyl or




.


83. The ~~method~~ compound of claim 82, wherein the compound is




,




,



,




, or



.

84. Use of a compound of Formula I,



(I)

or a pharmaceutically acceptable salt thereof ~~to a patient in need of such treatment~~,

wherein R_1, R_2, R_3, R_4 and R_5 are each independently







a) hydrogen;

b) halogen, -CN, -CF_3, or -NO_2;


c) C_1-C_8 alkyl or C_1-C_8 haloalkyl;

d) C_2-C_8 alkenyl or C_2-C_8 haloalkenyl;

e) C_2-C_8 alkynyl or C_2-C_8 haloalkynyl;


,

,

,

,

, or

.


95. Use of a compound of Formula II,



(II)

or a pharmaceutically acceptable salt thereof ~~to a patient in need of such treatment~~,


wherein A is $-OR_6$, $-CO_2R_6$, $-L-OC(O)R_6$, $-O-L-OC(O)R_6$, $-O-L-OC(O)OR_6$, $-OC(O)R_6$, $-OC(O)-L-OC(O)R_6$, $-OC(O)OR_6$, $-OC(O)O-L-C(O)R_7$, $-OC(O)O-L-C(O)OR_7$, -



(IV)

or a pharmaceutically acceptable salt thereof ~~to a patient in need of such treatment~~,

wherein A is -OR_6, -CO_2R_6, -L-OC(O)R_6, -O-L-OC(O)R_6, -O-L-OC(O)OR_6, -OC(O)R_6, -OC(O)-L-OC(O)R_6, -OC(O)OR_6, -OC(O)O-L-C(O)R_7, -OC(O)O-L-C(O)OR_7, -C(O)NR_6R_7, -CNR_6R_7, -OC(O)NR_6R_7, -OC(O)N(R_6)-L-OC(O)R_7, -OC(O)N(-L-OC(O)R_7)(-L-OC(O)R_8),



; and

B and C are each independently hydrogen, halogen, -CF_3, -CN, C_1-C_8 alkyl, phenyl, -OR_6, or -C(O)OR_6, or B and C when taken together form an optionally substituted 4- to 8-membered carbocyclic or heterocyclic ring, wherein the ring is saturated, unsaturated or aromatic; and


R_9 and R_{10} are each independently hydrogen, halogen, oxygen, C_1-C_8 alkyl, C_1-C_8 haloalkyl, C_2-C_8 alkenyl, C_2-C_8 haloalkenyl, C_2-C_8 alkynyl, C_2-C_8 haloalkynyl, optionally substituted aryl, optionally substituted heteroaryl, -OR_6, -SR_6, -NR_6R_7, -(C_1-C_8 alkyl)-NR_6R_7, -(C_1-C_8 haloalkyl)-NR_6R_7, -(C_2-C_8 alkenyl)-NR_6R_7, -(C_2-C_8 haloalkenyl)-NR_6R_7, -(C_2-C_8 alkynyl)-NR_6R_7, -(C_2-C_8 haloalkyl)-NR_6R_7, -L-R_{11}; or R_9 and R_{10} taken together form a monocyclic or bicyclic optionally substituted carbocyclic or heterocyclic ring, wherein the ring is saturated, unsaturated or aromatic;

wherein R_{11} is optionally substituted aryl or optionally substituted heteroaryl;

m and n are each independently an integer from 0 to 2;

Y is -CH_2-, -O-, -NR_7-, or -S-;

p is an integer from 1 to 3;

Z is  ;